Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + rebamipide
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Celecoxib + rebamipide is a combination of two small molecule drugs used primarily to manage pain and inflammation while protecting the gastrointestinal (GI) mucosa. Celecoxib is a selective nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-2 (COX-2), reducing the synthesis of prostaglandins involved in pain and inflammation. It is indicated for conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and menstrual cramps[1][5][6]. Rebamipide is an amino acid derivative with gastroprotective properties; it enhances mucosal defense by promoting prostaglandin synthesis and gastric mucus secretion while scavenging free radicals. Rebamipide is used to treat gastritis, peptic ulcers, gastroduodenal ulcers, and as prophylaxis against NSAID-induced GI injury[3][4][8]. The combination aims to provide effective anti-inflammatory therapy with reduced risk of upper GI complications associated with NSAIDs[2][8].
- Other names
- celecoxib/rebamipide
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on celecoxib + rebamipide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + rebamipide.